Diligence memo · auto-generated · as of July 2, 2026
EarlyCell, Inc.
EarlyCell, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
EarlyCell, Inc. operates in Biotechnology, based in CLEVELAND.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
EarlyCell, Inc. has raised $800K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $800K on 2015-06-25.
Most recent recorded round closed around 2015-06-25.
Valuation (modeled)modeled
Provath models EarlyCell, Inc. at approximately $44M (range $427K–$501M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.79× the median modeled value of Pre-Seed Biotechnology companies in 2013–2015 (131 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 11.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 15% of Biotechnology peers (4293 compared).
Modeled value ranks above 43% of those peers.
Closest niche peers: Imanis Life Sciences, LLC, Truminim, LLC, Direct Spinal Therapeutics, Inc., Universal Biosensors Inc, One World Lab, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.